← 홈

Antibody · 폐암 (NSCLC)

212개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 212개
AntibodystaleAstraZenecaPhase 2

durvalumab (Imfinzi, Durvalumab plus radiotherapy)

Non-small Cell Lung Cancer Stage III · Non-small Cell Lung Cancer Stage III

#Non-smallCellLungCancerStageIII#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleAstraZenecaPhase 2

durvalumab (Imfinzi, Durvalumab with etoposide and Carboplatin/Cisplatin)

Large Cell Neuroendocrine Carcinoma of the Lung · Large Cell Neuroendocrine Carcinoma of t

#LargeCellNeuroendocrineCarcinoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleAstraZenecaPhase 2

durvalumab (Imfinzi, Durvalumab, etoposide, and cisplatin/carboplatin followed by durvalumab and olaparib)

Lung Cancer; Small Cell Lung Cancer · Lung Cancer

#LungCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleNational Cancer Center, KoreaPhase 2

Erlotinib plus Bevacizumab (Erlotinib plus Bevacizumab)

EGFR Positive Non-small Cell Lung Cancer · EGFR

#EGFR#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab (Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleBrightPath BiotherapeuticsPhase 2

pembrolizumab (Keytruda, GRN-1201 + Pembrolizumab)

Metastatic NSCLC · Metastatic NSCLC

#MetastaticNSCLC#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleHunan Province Tumor HospitalPhase 2

IBI-323 combined with bevacizumab plus Platinum (IBI-323 combined with bevacizumab plus Platinum)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleShanghai Pulmonary Hospital, Sh…Phase 2

IBI310+Sintilimab (IBI310+Sintilimab)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleBristol-Myers SquibbPreclinical

nivolumab (Opdivo, Immuno-oncology-based therapy, excluding nivolumab-based regimens, Immuno-oncology-based therapy (excluding nivolumab-based regimens) with chemotherapy)

Non-small Cell Lung Cancer (NSCLC) · Non-small Cell Lung Cancer (NSCLC)

#Non-smallCellLungCancerNSCLC#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleUniversity Medical Center Groni…Preclinical

durvalumab (Imfinzi, Immunotherapy: adjuvant durvalumab)

Carcinoma, Non-Small-Cell Lung · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#Antibody#Preclinical#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleUniversity of ChicagoPhase 2

for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab (Investigator Choice Immunotherapy, Investigator Choice Immunotherapy (for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab))

Non-Small Cell Lung Cancer; Metastatic Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, Ipilimumab plus nivolumab plus guadecitabine)

Melanoma; Non Small Cell Lung Cancer · Melanoma

#Melanoma#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleInSightecPhase 3

Iptilimumab (Iptilimumab)

Brain Tumor; Non Small Cell Lung Cancer · Brain Tumor

#BrainTumor#Antibody#Phase3#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleShanghai Pulmonary Hospital, Sh…Phase 2

LM-108+Sintilimab (LM-108+Sintilimab)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleAline Fusco Fares, MDPhase 2

nivolumab (Opdivo, Low-dose nivolumab combined with platinum-based doublet chemotherapy)

Lung Cancer, Nonsmall Cell; Non-Small Cell Lung Cancer NSCLC · Lung Cancer, Nonsmall Cell

#LungCancerNonsmallCell#Antibody#Phase2#항체#면역항체+5
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 3

Bevacizumab Biosimilar Drug (MB02, MB02 (Bevacizumab Biosimilar Drug))

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase3#항체#면역항체+2
효능 ORR 40.3%임상시험 1상태 ACTIVE
AntibodystaleAssistance Publique Hopitaux De…Phase 2

IPH2201 (Monalizumab, Monalizumab (IPH2201))

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleImmunityBio, Inc.Phase 2

atezolizumab (Tecentriq, N-803 + Atezolizumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleImmunityBio, Inc.Phase 2

atezolizumab (Tecentriq, N-803 + Atezolizumab + PD-L1 t-haNK)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · PD-L1

#PD-L1#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleImmunityBio, Inc.Phase 2

N-803 + Avelumab (N-803 + Avelumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+3
효능 ORR 6%임상시험 1상태 RECRUITING

6 / 11 페이지

← 이전다음 →